Glenmark Launches Generic Vancomycin in US

1 Minute Read Listen to Article
Share:    

May 18, 2026 10:18

x
Glenmark Pharma launches generic vancomycin hydrochloride injection in the US. Bioequivalent to Fresenius Kabi. Strengthens injectable portfolio.
New Delhi, May 18 (PTI) Glenmark Pharmaceuticals Ltd on Monday announced the launch of the generic version of its antibacterial prescription vancomycin hydrochloride in the US.

The company's arm Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched vancomycin hydrochloride for Injection of strengths 500 mg/vial and 1 g/vial, Glenmark said in a statement.


The injection is bioequivalent and therapeutically equivalent to the reference listed drug, vancomycin hydrochloride for Injection 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC, it added.

Commenting on the launch, Glenmark President & Business Head, North America Marc Kikuchi said it "strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients".

Citing IQVIA sales data for the 12-month period ending March 2026, Glenmark said the vancomycin hydrochloride for Injection 500 mg/vial and 1 g/vial market achieved annual sales of approximately USD 37.9 million.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback